E-resources
Peer reviewed
-
Perez-Moreiras, Jose V.; Gomez-Reino, Juan J.; Maneiro, Jose R.; Perez-Pampin, Eva; Romo Lopez, Angel; Rodríguez Alvarez, Fernando M.; Castillo Laguarta, Jesús M.; del Estad Cabello, Aurora; Gessa Sorroche, María; España Gregori, Enrique; Sales-Sanz, Marco; Gomez-Reino, Juan J.; Maneiro, Jose; Tome Martinez de Rituerto, Maria A.; Pampin, Eva Perez; Perez-Moreiras, Jose V.; Alvarez, Alejandro; Lopez, Angel Romo; Troyano, Juan; Niño, Cristina; Vico, Eva; Montañez Zorrilla, Maria C.; Sanz, Marco Sales; Martín Ucero, Ana M.; Revenga, Marcelino; Gregori, Enrique España; Pérez Lazaro, Antonia M.; Todoli, José A.; Gonzalez Alejos, Alba M.; Rodríguez Alvarez, Fernando M.; Díaz, César; Cubero Marcos, José M.; Castillo Laguarta, Jesús M.; Polo, Angel Dominguez; Lavilla, Laura; Ginés, Cilia Peralta; Cabello, Aurora del Estad; Gómez Escobar, Antonio J.; Díaz, Concepción; Sarabia, Federico Navarro; Hernández, Tomás Martín; Sorroche, María Gessa; Navarro, Elena; Rubio, Esteban; Blandón, Rafael Villanueva; Maiquez, María P.
American journal of ophthalmology, November 2018, 2018-11-00, 20181101, Volume: 195Journal Article
To demonstrate the efficacy of the anti-interleukin-6 receptor monoclonal antibody tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy (GO). Double-masked randomized clinical trial. Setting and Participants: Thirty-two adults with moderate-to-severe corticosteroid-resistant GO from 10 medical centers in Spain were randomized (1:1). Intervention: Randomization to either 8 mg/kg body weight tocilizumab or placebo administered intravenously at weeks 0, 4, 8, and 12, and follow-up for an additional 28 weeks. Main Outcomes and Measures: The primary outcome was the proportion of patients with a change from baseline to week 16 of at least 2 in the clinical activity score (CAS). The primary outcome was met by 93.3% (95% confidence interval CI 70.1%-98.8%) of the patients receiving tocilizumab and 58.8% (36%-78.3%) receiving placebo (P = .04; odds ratio, 9.8 CI 1.3-73.2). A significant difference was also observed in the proportion of patients achieving a CAS < 3 (86.7% CI 62.1%-96.2% vs 35.2% CI 17.3%-58.7%, P = .005; OR 11.9 CI 2.1-63.1) at week 16. Additionally, a larger proportion of patients with improvement in the European Group on GO–proposed composite ophthalmic score at week 16 (73.3% CI 48%-89.1% vs 29.4% CI 13.2%-53.1%; P = .03), and exophthalmos size change from baseline to week 16 (-1.5 -2.0 to 0.5 mm vs 0.0 -1.0 to 0.5 mm; P = .01) were seen with tocilizumab. One patient experienced a moderate increase in transaminases at week 8; another had an acute pyelonephritis at week 32 in the tocilizumab-treated group. Tocilizumab offers a meaningful improvement in activity and severity in corticosteroid-resistant GO. This trial justifies further studies to characterize the role of tocilizumab in GO.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.